The latest approval for Kadcyla is for HER2-positive early breast cancer patients with residual invasive disease after being subjected to neoadjuvant treatment with taxane and Herceptin (trastuzumab). The
The post Roche’s Kadcyla gets FDA nod for adjuvant treatment of HER2+ early breast cancer appeared first on Pharmaceutical Business review.